Last quarter (Q4 2023), MiNK Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, MiNK Therapeutics's net income was $-5.46M. See MiNK Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 689.63K
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 22.92M	$ 22.92M	$ 30.95M	$ 28.36M	$ 10.80M	$ 23.48M
Operating Income	$ -22.92M	$ -22.92M	$ -30.95M	$ -28.36M	$ -10.80M	$ -22.79M
Net Non Operating Interest Income Expense	$ 463.26K	$ 463.26K	-	$ -2.43M	$ -2.44M	$ -1.56M
Other Income Expense	$ 10.00	$ 10.00	$ -2.70M	$ -577.43K	$ -3.00M	$ 551.24K
Pretax Income	$ -22.46M	$ -22.46M	$ -27.99M	$ -30.21M	$ -16.24M	$ -23.80M
Tax Provision	$ -1.69M	$ -1.69M	$ -348.00K	$ -511.00K	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -22.46M	$ -22.46M	$ -27.99M	$ -30.21M	$ -16.24M	$ -23.80M
Basic EPS	$ -0.66	$ -0.65	$ -0.83	$ -1.16	$ -0.60	$ -0.93
Diluted EPS	$ -0.66	$ -0.65	$ -0.83	$ -1.16	$ -0.60	$ -0.93
Basic Average Shares	$ 137.44M	$ 34.36M	$ 33.67M	$ 26.03M	$ 26.95M	$ 25.55M
Diluted Average Shares	$ 137.44M	$ 34.36M	$ 33.67M	$ 26.03M	$ 26.95M	$ 25.55M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 22.92M	$ 22.92M	$ 30.95M	$ 28.36M	$ 10.80M	$ 23.48M
Net Income From Continuing And Discontinued Operation	$ -22.46M	$ -22.46M	$ -27.99M	$ -30.21M	$ -16.24M	$ -23.80M
Normalized Income	$ -16.09M	$ -24.15M	-	-	$ -16.24M	$ -23.80M
Interest Expense	-	-	-	-	$ 2.44M	$ 1.56M
EBIT	$ -22.92M	$ -22.92M	$ -27.99M	$ -27.78M	$ -13.80M	$ -22.24M
EBITDA	$ -16.43M	$ -22.72M	$ -27.87M	$ -27.70M	$ -13.74M	$ -22.20M

Currency in USD

MiNK Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing